EmblemHealth Inc., a not-for-profit insurance company, has filed a proposed class action lawsuit against an AstraZeneca subsidiary. The lawsuit alleges that the AstraZeneca unit committed fraud against the U.S. Patent and Trademark Office to delay the introduction of generic competitors to its blood disorder medication, Soliris. The case revolves around allegations of unlawful actions taken to maintain market exclusivity and control over Soliris, a high-cost treatment crucial for specific rare blood disorders.
The suit raises significant questions about the pharmaceutical industry’s strategies for extending patent life and potentially hindering market competition, which could impact pricing and accessibility of crucial medications. Legal observers will be watching closely as this case unfolds, given its potential implications for patent law interpretation and competitive practices in the pharmaceutical sector.
Further details about the case can be found in this article by Adam Lidgett on Law360.